EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea

Sojung Han iD, Do Young Kim iD, Ho Yeong Lim iD, Jung-Hwan Yoon iD, Baek-Yeol Ryoo iD, Yujeong Kim iD, Kookhee Kim iD, Bo Yeon Kim iD, So Young Yi iD, Dong-Sook Kim iD, Do-Yeon Cho iD, Jina Yu iD und 2 weitere

Gut and Liver · 15.01.2024 · 18 (1) · 116-124

DOI: 10.5009/gnl220406 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Gut and Liver, online erschienen am 19.06.2023. Verfasst von Sojung Han und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeongbu, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsChemoembolization, TherapeuticHumansSorafenibRetrospective StudiesNiacinamidePhenylurea CompoundsTreatment Outcome

Stichwörter der Autor:innen

CarcinomaSorafenibSurvivalhepatocellular

Substanzen

SorafenibAntineoplastic AgentsNiacinamidePhenylurea Compounds

Autor:innen und Institutionen

  • Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University College of Medicine, Uijeongbu, Korea.
  • Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Health Insurance Review and Assessment, Wonju, Korea.

ORCID-Profile: Sojung Han, Do Young Kim, Ho Yeong Lim, Jung-Hwan Yoon, Baek-Yeol Ryoo, Yujeong Kim, Kookhee Kim, Bo Yeon Kim, So Young Yi, Dong-Sook Kim, Do-Yeon Cho, Jina Yu, Suhyun Kim, Joong-Won Park

Zitieren

APA

Han, S., Kim, D. Y., Lim, H. Y., Yoon, J. H., Ryoo, B. Y., Kim, Y., Kim, K., Kim, B. Y., Yi, S. Y., Kim, D. S., Cho, D. Y., Yu, J., Kim, S., & Park, J. W. (2024). Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea. Gut and Liver, 18(1), 116-124. https://doi.org/10.5009/gnl220406

Vancouver

Han S, Kim DY, Lim HY, Yoon JH, Ryoo BY, Kim Y, et al. Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea. Gut and Liver. 2024;18(1):116-124. doi:10.5009/gnl220406

BibTeX
@article{Han2024,
  author = {Han, Sojung and Kim, Do Young and Lim, Ho Yeong and Yoon, Jung-Hwan and Ryoo, Baek-Yeol and Kim, Yujeong and Kim, Kookhee and Kim, Bo Yeon and Yi, So Young and Kim, Dong-Sook and Cho, Do-Yeon and Yu, Jina and Kim, Suhyun and Park, Joong-Won},
  title = {Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea},
  journal = {Gut and Liver},
  year = {2024},
  volume = {18},
  number = {1},
  pages = {116--124},
  doi = {10.5009/gnl220406}
}
Kostenlos starten →